Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The immunogenicity against variants of concern and reactogenicity of four COVID-19 booster vaccinations following CoronaVac or ChAdOx1 nCoV-19 primary series

Nasikarn Angkasekwinai, Suvimol Niyomnaitham, Jaturong Sewatanon, Supaporn Phumiamorn, Kasama Sukapirom, Sansnee Senawong, Surakameth Mahasirimongkol, Zheng Quan Toh, Pinklow Umrod, Thitiporn Somporn, Supaporn Chumpol, Kanokphon Ritthitham, Yuparat Jantraphakorn, Kanjana Srisutthisamphan, View ORCID ProfileKulkanya Chokephaibulkit
doi: https://doi.org/10.1101/2021.11.29.21266947
Nasikarn Angkasekwinai
1Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suvimol Niyomnaitham
2Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
3Siriraj Institute of Clinical Research (SICRES), Mahidol University, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaturong Sewatanon
4Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Supaporn Phumiamorn
5Department of Medical Sciences, Ministry of Public Health, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kasama Sukapirom
6Biomedical Research Incubator Unit, Department of Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
7Siriraj Center of Research Excellence in Microparticle and Exosome in Disease, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sansnee Senawong
8Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Surakameth Mahasirimongkol
5Department of Medical Sciences, Ministry of Public Health, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zheng Quan Toh
9Murdoch Children’s Research Institute, Parkville, Victoria, Australia
10Department of Pediatrics, The University of Melbourne, Parkville, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pinklow Umrod
8Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thitiporn Somporn
5Department of Medical Sciences, Ministry of Public Health, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Supaporn Chumpol
5Department of Medical Sciences, Ministry of Public Health, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kanokphon Ritthitham
5Department of Medical Sciences, Ministry of Public Health, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuparat Jantraphakorn
12Virology and Cell Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathumthani 12120, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kanjana Srisutthisamphan
12Virology and Cell Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathumthani 12120, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kulkanya Chokephaibulkit
3Siriraj Institute of Clinical Research (SICRES), Mahidol University, Thailand
11Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kulkanya Chokephaibulkit
  • For correspondence: kulkanya.cho@mahidol.ac.th
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Importance The immunogenicity of COVID-19 booster vaccine following inactivated or chimpanzee adenoviral vector COVID-19 vaccination is unclear.

Objectives To determine the reactogenicity and immunogenicity of different booster vaccine following CoronaVac (by Sinovac) or ChAdOx1 (by AstraZeneca) primary series vaccination.

Design Prospective, non-randomized, open-labeled cohort study

Setting A single center, tertiary care university-based hospital in Bangkok.

Participants Healthy adults who received a 2-dose homologous primary series of either CoronaVac or ChAdOx1 8-12 weeks earlier.

Intervention One of the four booster vaccines: BBIBP-CorV (by Sinopharm), ChAdOx1, 30μg-BNT162b2 (by Pfizer) or 15μg-BNT162b2 vaccines.

Main Outcomes and Measures Self-reported adverse events (AEs) for 7 days following vaccination were collected by electronic diary system. The immunogenicity was determined by IgG against receptor binding domain (RBD) of the SARS-CoV-2 spike protein, 50% plaque reduction neutralization test (PRNT50) against Delta and Beta variants, 50% pseudovirus neutralizing antibody (PVNT50) against Delta and Omicron variants, and whole blood interferon gamma (IFN-□) releasing assay.

Results Among the 352 participants (179 in CoronaVac- and and 173 in ChAdOx1-prime group), 285 (81%) were female, and the median age was 39 (interquartile range: 31-47) years. The AEs for all booster vaccines were mild to moderate. Two weeks post-booster, 30μg-BNT162b2 induced the highest anti-RBD IgG concentration in the CoronaVac- and ChAdOx1-prime groups (5152 and 2364 BAU/mL), followed by 15μg-BNT162b2 (3981 and 1962 BAU/mL), ChAdOx1 (1358 and 246 BAU/mL), and BBIBP-CorV (154 and 128 BAU/mL), respectively. The PRNT50 against the Delta variant were also highest with 30μg-BNT162b2 (411 and 470) and 15μg-BNT162b2 (499 and 358); followed by ChAdOx1 (271 and 69), and BBIBP-CorV (61.3 and 49) for CoronaVac and ChAdOx1-prime, respectively. Similar trend was observed for PRNT50 against the Beta variant. The PVNT50 against the Omicron variant was highest with 30μg-BNT162b2 (543 and 521) followed by 15μg-BNT162b2 (551 and 232) for CoronaVac- and ChAdOx1-prime, respectively. BNT162b2 vaccine also induced the highest IFN-□ response in both CoronaVac- and ChAdOx1-prime groups.

Conclusions and Relevance Heterologous boosting vaccination with BNT162b2 following CoronaVac or ChAdOx1 primary series is the most immunogenic against SARS-CoV-2 variants. A lower dose BNT162b2 may be used as booster in settings with limited vaccine supply.

Trial Registration Thaichinicaltrials.org (TCTR20210719006).

Question Which COVID-19 booster vaccine is most immunogenic following 2-dose CoronaVac or ChAdOx1 primary series?

Findings This prospective cohort study found that BNT162b2 given half or standard dosage as a booster (3rd dose) vaccination induced the highest humoral responses against the original SARS-CoV-2 Wuhan strain, and the SARS-CoV-2 variants (Delta, Beta, and Omicron). Boosting with inactivated vaccine (BBIBP-CorV) induced poor humoral and cellular immune responses.

Meaning Heterologous boosting with half or standard dosage of BNT162b2 following CoronaVac or ChAdOx1 primary series is safe and highly immunogenic, and likely to confer protection against the SARS-CoV-2 variants.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

TCTR20210719006

Funding Statement

This study was supported by the National Research Council of Thailand. The Abbott Laboratories Ltd. partially supported the reagents for the anti-SARS-CoV-2 RBD IgG in this study. The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was approved by the Siriraj Institutional Review Board, Thailand (COA no. Si 537/2021).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 19, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The immunogenicity against variants of concern and reactogenicity of four COVID-19 booster vaccinations following CoronaVac or ChAdOx1 nCoV-19 primary series
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The immunogenicity against variants of concern and reactogenicity of four COVID-19 booster vaccinations following CoronaVac or ChAdOx1 nCoV-19 primary series
Nasikarn Angkasekwinai, Suvimol Niyomnaitham, Jaturong Sewatanon, Supaporn Phumiamorn, Kasama Sukapirom, Sansnee Senawong, Surakameth Mahasirimongkol, Zheng Quan Toh, Pinklow Umrod, Thitiporn Somporn, Supaporn Chumpol, Kanokphon Ritthitham, Yuparat Jantraphakorn, Kanjana Srisutthisamphan, Kulkanya Chokephaibulkit
medRxiv 2021.11.29.21266947; doi: https://doi.org/10.1101/2021.11.29.21266947
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
The immunogenicity against variants of concern and reactogenicity of four COVID-19 booster vaccinations following CoronaVac or ChAdOx1 nCoV-19 primary series
Nasikarn Angkasekwinai, Suvimol Niyomnaitham, Jaturong Sewatanon, Supaporn Phumiamorn, Kasama Sukapirom, Sansnee Senawong, Surakameth Mahasirimongkol, Zheng Quan Toh, Pinklow Umrod, Thitiporn Somporn, Supaporn Chumpol, Kanokphon Ritthitham, Yuparat Jantraphakorn, Kanjana Srisutthisamphan, Kulkanya Chokephaibulkit
medRxiv 2021.11.29.21266947; doi: https://doi.org/10.1101/2021.11.29.21266947

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (559)
  • Anesthesia (135)
  • Cardiovascular Medicine (1774)
  • Dentistry and Oral Medicine (239)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10824)
  • Forensic Medicine (8)
  • Gastroenterology (595)
  • Genetic and Genomic Medicine (2962)
  • Geriatric Medicine (289)
  • Health Economics (534)
  • Health Informatics (1935)
  • Health Policy (836)
  • Health Systems and Quality Improvement (746)
  • Hematology (294)
  • HIV/AIDS (634)
  • Infectious Diseases (except HIV/AIDS) (12530)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (89)
  • Nephrology (325)
  • Neurology (2815)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (560)
  • Occupational and Environmental Health (600)
  • Oncology (1475)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (258)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (869)
  • Pharmacology and Therapeutics (368)
  • Primary Care Research (339)
  • Psychiatry and Clinical Psychology (2650)
  • Public and Global Health (5386)
  • Radiology and Imaging (1019)
  • Rehabilitation Medicine and Physical Therapy (598)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (291)
  • Sports Medicine (279)
  • Surgery (328)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (127)